Im­muno­van­t's plans for au­toim­mune as­set; Wall Street wor­ries about Mod­er­na’s RSV can­di­date 

Plus, news about No­vo Hold­ings, Grit­stone Bio, In­vivyd and Sci­ence 37:

Im­muno­vant out­lines big plans for its au­toim­mune pro­gram: The biotech now ex­pects to launch four to five “po­ten­tial­ly reg­is­tra­tional” tri­als for IMVT-1402 by March 2025 and stud­ies in up to 10 in­di­ca­tions by March 2026. Im­muno­vant tout­ed the as­set’s “best-in-class” po­ten­tial af­ter a Phase I study in healthy vol­un­teers read out pos­i­tive­ly last No­vem­ber. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER